Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, ...

(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged ...

Bavarian Nordic’s mpox vaccine Jynneos generated a similar immune response in adolescents as it did in adults, offering ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in ...

After approving Bavarian Nordic’s mpox vaccine in September for use in adults, the World Health Organisation has given the ...

The World Health Organization approved the use of Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, ...

Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpoxThe World Health ...

The World Health Organization has approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17, a group considered ...

Interim results of a phase 2 trial indicate that the mpox vaccine MVA-VN has an immune response in adolescents similar to ...

A clinical trial by the US National Institutes of Health (NIH) has shown that Bavarian Nordic’s mpox vaccine induced an antibody response in adolescents equivalent to that of adults. The interim ...

Oct 14 (Reuters) - The World Health Organization said on Monday it had approved Bavarian Nordic's (BAVA.CO), opens new tab mpox vaccine for adolescents aged 12 to 17 years, an age group considered ...